PCC0208018 exerts antitumor effects by activating effector T cells

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Melanoma's poor prognosis is linked to immune suppression, highlighting the role of immune alterations in its development and spread.
• Existing immunotherapies often target the PD-1/PD-L1 pathway, but alternative strategies are needed to enhance anti-tumor immunity.

Purpose of the Study:

• To investigate the immunomodulatory and anti-tumor effects of the small-molecule compound PCC0208018.
• To elucidate the molecular mechanisms underlying PCC0208018's action on T cells and melanoma.

Main Methods:

• In vitro studies using human peripheral blood mononuclear cells (PBMCs) to assess T cell proliferation, cytokine release (IFN-γ, IL-2), and signaling pathway activation (AKT, ERK).
• In vivo studies using B16-F10 melanoma-bearing mice to evaluate tumor growth inhibition and changes in tumor-infiltrating T cells (CD3+, CD4+, CD8+).
• Utilized PI3K inhibitor (GDC-0941) to confirm pathway involvement.

Main Results:

• PCC0208018 enhanced T cell proliferation and cytokine production (IFN-γ, IL-2) without blocking PD-1/PD-L1 interactions.
• The compound activated the PI3K/AKT and MEK/ERK signaling pathways in PBMCs.
• In vivo, PCC0208018 significantly inhibited melanoma tumor growth and increased CD3+, CD4+, and CD8+ T cell infiltration in tumors.

Conclusions:

• PCC0208018 demonstrates potent anti-tumor activity by enhancing T cell function through the PI3K/AKT and MEK/ERK pathways.
• This compound represents a potential therapeutic agent for melanoma, offering a novel mechanism of action independent of PD-1/PD-L1 blockade.